BR9916041A - Composto, composição farmacêutica, e, métodospara inibir a replicação de um vìrus do herpes epara tratar um paciente sofrendo de uma infecçãopor vìrus do herpes - Google Patents

Composto, composição farmacêutica, e, métodospara inibir a replicação de um vìrus do herpes epara tratar um paciente sofrendo de uma infecçãopor vìrus do herpes

Info

Publication number
BR9916041A
BR9916041A BR9916041-2A BR9916041A BR9916041A BR 9916041 A BR9916041 A BR 9916041A BR 9916041 A BR9916041 A BR 9916041A BR 9916041 A BR9916041 A BR 9916041A
Authority
BR
Brazil
Prior art keywords
carbon atoms
alkyl
herpes virus
virus
carbon
Prior art date
Application number
BR9916041-2A
Other languages
English (en)
Inventor
Jonathan David Bloom
Martin Joseph Digrandi
Russell Georgedushin
Stanley Albert Lang
Bryan Mark O'hara
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Publication of BR9916041A publication Critical patent/BR9916041A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/16—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C335/20—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/16—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C335/22—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA, E, MéTODOSPARA INIBIR A REPLICAçãO DE UM VìRUS DO HERPES EPARA TRATAR UM PACIENTE SOFRENDO DE UMA INFECçãOPOR VìRUS DO HERPES". Em que R~ 1~-R~ 5~ sãoindependentemente selecionados dentre hidrogênio, alquila de 1 a6 átomos de carbono, alquenila de 2 a 6 átomos de carbono,alquinila de 2 a 6 átomos de carbono, per-haloalquila de 1 a 6átomos de carbono, cicloalquila de 3 a 10 átomos de carbono,heterocicloalquila de 3 a 10 membros de carbono, arila, heteroarila,halogênio, -CN, -NO~ 2~, -CO~ 2~R~ 6~, COR~ 6~, -OR~ 6~,-SR~ 6~, -SOR~ 6~, -SO~ 2~R~ 6~, -CONR~ 7~R~ 8~, -NR~6~N (R~ 7~R~ 8~), -N(R~ 7~R~ 8~) ou W-Y-(CH~ 2~)~ n~-Z,com a condição de que pelo menos um de R~ 1~-R~ 5~ não éhidrogênio; ou R~ 2~ e R~ 3~ ou R~ 3~ e R~ 4~, tomados juntos,formam uma heterocicloalquila de 3 a 7 membros ou heteroarila de3 a 7 membros; R~ 6~ e R~ 7~ são independentementehidrogênio, alquila de 1 a 6 átomos de carbono, perhaloalquila de 1a 6 átomos de carbono, ou arila; R~ 8~ é hidrogênio, alquila de 1 a6 átomos de carbono, per-haloalquila de 1 a 6 átomos de carbono,cicloalquila de 3 a 10 átomos de carbono, heterocicloalquila de 3 a10 membros, arila ou heteroarila, ou R~ 7~ e R~ 8~, tomadosjuntos, podem formar uma heterocicloalquila de 3 a 7 membros; R~9~-R~ 12~ são independentemente hidrogênio, alquila de 1 a 4átomos de carbono, per-haloalquila de 1 a 4 átomos de carbono,halogênio, alcoxi de 1 a 4 átomos de carbono, ou ciano, ou R~ 9~e R~ 10~ ou R~ 11~, e R~ 12~ podem ser tomados juntos paraformar arila de 5 a 7 átomos de carbono; W é 0, NR~ 6~ ou estáausente; Y é -(CO)-ou -(CO~ 2~)-, ou está ausente; Z é alquila de 1a 4 átomos de carbono, -CN, -CO~ 2~R~ 6~, -COR~ 6~, CONR~7~R~ 8~, -OCOR~ 6~, -NR~ 6~COR~ 7~, -OCONR~ 6~, -OR~6~, -SOR~ 6~, -SO~ 2~ R~ 6~, SR~ 6~N(R~ 7~R~ 8~), -N (R~7~R~ 8~) ou fenila; G é alquila de 1 a 6 átomos de carbono, X éuma ligação, -NH, alquila de 1 a 6 átomos de carbono, alquenila de1 a 6 átomos de carbono, alcoxi de 1 a 6 átomos de carbono,tioalquila de 1 a 6 átomos de carbono, alquilamino de 1 a 6 átomosde carbono, ou (CH)J; J é alquila de 1 a 6 átomos de carbono,cicloalquila de 3 a 7 átomos de carbono, fenila ou benzila; e n é uminteiro de 1 a 6; ou sais 1 farmacêuticos dos mesmos, sãoutilizáveis no tratamento de doenças associadas com vírus doherpes incluindo citomegalovírus humano, vírus de herpes simplex,vírus Epstein-Barr, vírus de varicella-zoster, vírus de herpeshumano 6 e 7, e vírus de herpes de Kaposi.
BR9916041-2A 1998-12-09 1999-12-06 Composto, composição farmacêutica, e, métodospara inibir a replicação de um vìrus do herpes epara tratar um paciente sofrendo de uma infecçãopor vìrus do herpes BR9916041A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20831698A 1998-12-09 1998-12-09
PCT/US1999/028844 WO2000034237A2 (en) 1998-12-09 1999-12-06 Acetamide and substituted acetamide-containing thiourea inhibitors of herpes viruses

Publications (1)

Publication Number Publication Date
BR9916041A true BR9916041A (pt) 2001-12-04

Family

ID=22774137

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9916041-2A BR9916041A (pt) 1998-12-09 1999-12-06 Composto, composição farmacêutica, e, métodospara inibir a replicação de um vìrus do herpes epara tratar um paciente sofrendo de uma infecçãopor vìrus do herpes

Country Status (15)

Country Link
EP (1) EP1137633A2 (pt)
JP (1) JP2002531544A (pt)
KR (1) KR20010087413A (pt)
CN (1) CN1333750A (pt)
AU (1) AU3111200A (pt)
BR (1) BR9916041A (pt)
CA (1) CA2350899A1 (pt)
CZ (1) CZ20012060A3 (pt)
EA (1) EA200100640A1 (pt)
HU (1) HUP0104944A3 (pt)
IL (1) IL143204A0 (pt)
NO (1) NO20012834L (pt)
PL (1) PL349131A1 (pt)
WO (1) WO2000034237A2 (pt)
ZA (1) ZA200104142B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6166028A (en) * 1998-12-09 2000-12-26 American Home Products Corporation Diaminopuridine-containing thiourea inhibitors of herpes viruses
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
WO2001064642A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
JP4690889B2 (ja) * 2002-10-24 2011-06-01 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング メチレン尿素誘導体
US7220768B2 (en) * 2003-02-11 2007-05-22 Wyeth Holdings Corp. Isoxazole-containing thiourea inhibitors useful for treatment of varicella zoster virus
EP1660661A2 (en) 2003-08-08 2006-05-31 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
CA2772017C (en) 2003-08-29 2016-05-31 Mitsui Chemicals, Inc. Agricultural/horticultural insecticide and method for using the same
AU2005221151A1 (en) 2004-03-09 2005-09-22 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
EP2074085A2 (en) * 2006-10-13 2009-07-01 Lica Pharmaceuticals A/S Anti-infective thiourea compounds
ES2382055T3 (es) 2006-11-02 2012-06-04 Millennium Pharmaceuticals, Inc. Métodos para sintetizar sales farmacéuticas de un inhibidor del factor Xa
CN108619123A (zh) * 2018-03-13 2018-10-09 武汉威立得生物医药有限公司 Tenovin-1在制备防治人类疱疹病毒感染药物中的应用
WO2019193541A1 (en) * 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
CN112807294B (zh) * 2019-11-18 2023-09-05 武汉大学 一种酰基硫脲类化合物在制备治疗或预防单纯疱疹病毒i型感染药物中的应用
WO2022150962A1 (en) * 2021-01-12 2022-07-21 Westlake Pharmaceutical (Hangzhou) Co., Ltd. Protease inhibitors, preparation, and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69830751T2 (de) * 1997-04-10 2006-05-18 Pharmacia & Upjohn Co. Llc, Kalamazoo Polyaromatische Verbindungen zur Behandlung von Herpes-Infektionen

Also Published As

Publication number Publication date
NO20012834L (no) 2001-08-07
CZ20012060A3 (cs) 2001-11-14
CN1333750A (zh) 2002-01-30
HUP0104944A2 (hu) 2002-04-29
EA200100640A1 (ru) 2001-12-24
CA2350899A1 (en) 2000-06-15
WO2000034237A2 (en) 2000-06-15
KR20010087413A (ko) 2001-09-15
AU3111200A (en) 2000-06-26
ZA200104142B (en) 2002-10-25
EP1137633A2 (en) 2001-10-04
NO20012834D0 (no) 2001-06-08
HUP0104944A3 (en) 2003-03-28
JP2002531544A (ja) 2002-09-24
WO2000034237A3 (en) 2000-11-23
IL143204A0 (en) 2002-04-21
PL349131A1 (en) 2002-07-01

Similar Documents

Publication Publication Date Title
BR9916041A (pt) Composto, composição farmacêutica, e, métodospara inibir a replicação de um vìrus do herpes epara tratar um paciente sofrendo de uma infecçãopor vìrus do herpes
EA200000990A1 (ru) Вич-ингибирующие производные пиримидина
DK0513104T3 (da) Anvendelse af et alfa-tocopherolphosphat eller et af dets derivater til fremstilling af kosmetiske, dermatologiske eller farmaceutiske præparater, og således opnåede præparater
EA200000993A1 (ru) Тризамещенные производные 1,3,5-триазина для лечения вич-инфекционных заболеваний
AU644095B2 (en) Antiviral compounds
CA2197319A1 (en) Lipid analogs for treating viral infections
NZ505362A (en) 4-hydroxyquinoline-3-carboxamides and -hydrazides useful as antiviral agents
BR9916086A (pt) Composto, composição farmacêutica, método para inibir a replicação de um vìrus do herpes, método para tratar um paciente sofrendo de uma infecção por vìrus do herpes
DK1224940T3 (da) Flydende formuleringer af interferon-beta
BR9916084A (pt) Composto, composição farmacêutica, e, processos para inibir a replicação de um vìrus da herpes, e para tratar um paciente sofrendo de uma infecção por vìrus da herpes
BR9916046A (pt) Composto, composição farmacêutica, e, processos para inibir a replicação de um vìrus herpes e para tratamento de um paciente que sofra de uma infecção do vìrus herpes
DK0534445T3 (da) Fremgangsmåde til fremstilling af et lægemiddel til oral eller topisk administrering ved behandling af Leishmaniasis
BR9916042A (pt) Composto, composição farmacêutica, e, processospara inibir a replicação de um vìrus herpes, e detratamento de um paciente que sofra de umainfecção do vìrus herpes
ATE173252T1 (de) Arylmorpholine, herstellung und verwendung
NO983090L (no) Terapeutiske forbindelser
EA200100639A1 (ru) Производные тиомочевины, содержащие гетероциклический карбоксамид и защитную группу фенилэтиленамина, в качестве ингибиторов вирусов герпеса
ATE59778T1 (de) Verwendung von sulfonamidderivaten zur herstellung eines antivirusmittels.
BR9915993A (pt) Composto, composição farmacêutica, processo para inibir a replicação de um vìrus herpes, e, processo para tratar um paciente sofrendo de uma infecção de vìrus herpes
PT1120415E (pt) Compostos de isoxazoliltiofeno substituido
FI906268A0 (fi) 2-formylbenzylfosfonsyraderivat, deras framstaellning och deras anvaendning vid vaord av sjukdomar foerorsakade av virus.
DK0586298T3 (da) Inhibitor af viral herpes simplex thymidin-kinase
ATE320260T1 (de) Schwefelhaltige phosphonoformat-derivate und deren verwendung.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]